thalidomide has been researched along with 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bassermann, F; Dove, S; Engleitner, T; Hassan, Z; Heinzlmeir, S; Kong, B; Krauß, L; Kuisl, A; Kuster, B; Lier, S; Mahboobi, S; Öllinger, R; Orben, F; Patricia Gloria Schäfer, A; Pongratz, H; Rad, R; Reichert, M; Saur, D; Schlag, C; Schneeweis, C; Schneider, C; Schneider, G; Sellmer, A; Wirth, M | 1 |
1 other study(ies) available for thalidomide and 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one
| Article | Year |
|---|---|
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Humans; Molecular Structure; Structure-Activity Relationship; Thalidomide; Thiazoles; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2022 |